Data collection and registry requirements under the AMNOG law - Changes in 2020

21/01/2020

Under the GSAV law, real-world evidence become important for health technology assessment (HTA) procedures under the AMNOG law.

This symposium focuses on post-launch data collection as well as registry studies and examines the requirements from the viewpoint of HTA bodies G-BA and IQWiG and of statutory health insurance GKV.

Berlin, Germany

More information

Ask for a Free trial and get access to the latest stories

Our coverage includes:
  • Health Care
  • Market Access
  • HTA – policies & practices
  • European medicine regulations
  • Drug safety issues
  • Pricing & Reimbursement
  • International medicines agencies

If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.

REQUEST

an initial 10 day temporary access of APM Health Europe.